Four years after entering a guilty plea in response to US generic price-fixing allegations, the former Sandoz US vice-president of business contracting and analytics, Hector Armando Kellum, will serve his sentence outside of a jail cell and pay a token criminal fine.

Viatris has revealed the early stages of a battle plan after it was knocked back on US FDA approval for its proposed once-monthly glatiramer acetate ‘GA Depot’ product, a follow-on to Teva’s Copaxone treatment for relapsing forms of multiple sclerosis.

Coherus BioSciences feels its bearing and clout in the US pegfilgrastim market will stand it in good stead as other players scrabble to compete on the more lucrative formulations of Amgen’s Neulasta.

Xbrane Biopharma’s recent CRL for its proposed US biosimilar to Lucentis has not prevented the Swedish company from announcing a successor to Bausch + Lomb to partner on the biosimilar’s US marketing and commercialization.

Fresenius Kabi enjoyed a good start to 2024, boosted by the recent US launch of its biosimilar tocilizumab product and a key licensing agreement signed with Teva – factors that have allowed the German generics and biosimilars giant to boost its financial guidance for 2024.

The US Federal Trade Commission is not resting on its laurels after seeing some success in its initial challenge to what it deems improper or irrelevant US patents that may be strangling cheaper generic competition.